SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis.
Bernardo F SpiazziGiovana F PiccoliLaura Fink WayerbacherJoão Pedro Neves LubiancaBruno G ScalcoMariana Hollmann SchefflerBruna L FragaVerônica ColpaniFernando GerchmanPublished in: Clinical journal of the American Society of Nephrology : CJASN (2024)
SGLT2 inhibitors consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels.
Keyphrases